Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.
about
Type II Fatty Acid Synthesis Is Essential for the Replication of Chlamydia trachomatisAntibiotics in the clinical pipeline at the end of 2015.In Vitro Evaluations and In Vivo Toxicity and Efficacy Studies of MFM501 against MRSA.Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureusHow bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics.Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening.Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections.Activation of Exogenous Fatty Acids to Acyl-Acyl Carrier Protein Cannot Bypass FabI Inhibition in Neisseria.Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase.A Pathogen-Selective Antibiotic Minimizes Disturbance to the Microbiome.Staphylococcus aureus fatty acid auxotrophs do not proliferate in miceEnvironmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials.Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).Structural characterisation of the fatty acid biosynthesis enzyme FabF from the pathogen Listeria monocytogenes.Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents.Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects.Bacterial fatty acid metabolism in modern antibiotic discovery.Exogenous fatty acid metabolism in bacteria.Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects.A pathway-directed positive growth restoration assay to facilitate the discovery of lipid A and fatty acid biosynthesis inhibitors in Acinetobacter baumannii.
P2860
Q27684448-AC12FE83-742D-47F3-95B4-9E0AD9657BF5Q30249262-63B5625C-9759-4F23-9C4A-F4234CD8BFE0Q33659793-714E7FC0-C061-4368-AF04-1DBF2A17172DQ34622399-2704A2CF-E1D8-4763-B8D8-C2A84AFBD5C1Q35172866-12E0E9E7-9166-44AC-8F49-7F222610AC52Q35586118-569681CE-6615-440E-81E3-ECA128859CA5Q35682692-D687BF12-73E4-44E6-B596-E3957C5713DBQ36419232-FA0EAC75-F622-418A-AD7B-0774A90386B5Q36951981-185691A6-4F2F-4671-AFE9-B60487477CEDQ37023140-A199B10A-E4E6-45F3-A434-F75C78038B14Q37263376-5F9C2957-C0D7-4C17-A1C4-5B308B9E27CFQ37329885-F49619B5-9785-4E44-B48E-C4E6B00AB83FQ37404976-A1988669-0935-48D8-A29D-0B6BC79904D3Q37550416-C81BF5D3-4E4D-4F37-99C0-D3B2F797FA5EQ38124842-2DF1D0C0-331A-49D5-BBAC-B11601FE49BCQ38442198-FB15B762-50DC-4B21-9F89-750535530675Q38964523-A37D8C3C-E662-44CF-B571-A0DF2C78DCE7Q39408643-A88C1E40-497C-411F-8992-F308A9F0FC48Q40968594-A779DE68-EDBD-4CB3-ABD0-C80AC4B39133Q52689133-03F109A7-0526-4C04-9FD7-17514CBAA5D5
P2860
Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Pharmacokinetics, pharmacodyna ...... murine thigh infection model.
@ast
Pharmacokinetics, pharmacodyna ...... murine thigh infection model.
@en
type
label
Pharmacokinetics, pharmacodyna ...... murine thigh infection model.
@ast
Pharmacokinetics, pharmacodyna ...... murine thigh infection model.
@en
prefLabel
Pharmacokinetics, pharmacodyna ...... murine thigh infection model.
@ast
Pharmacokinetics, pharmacodyna ...... murine thigh infection model.
@en
P2093
P2860
P1476
Pharmacokinetics, pharmacodyna ...... murine thigh infection model.
@en
P2093
Barry Hafkin
David P Nicolau
Mary A Banevicius
Nachum Kaplan
P2860
P356
10.1179/1973947812Y.0000000061
P577
2013-02-01T00:00:00Z